Showing results (311-320 of 392) with videos related to
Sort By:
Pageof 40
Haematologica|April 11, 2020
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center studyLesley-Ann Sutton, Viktor Ljungström, Anna Enjuanes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.Blood|October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W Flinn, Peter Hillmen, Marco Montillo, et al.Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.Leukemia|February 12, 2020
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupManuela A Hoechstetter, Raymonde Busch, Barbara Eichhorst, et al.Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.Leukemia|April 23, 2026
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemiaCosima Drewes, Cristina López, Nnamdi Okeke, et al.Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.Pageof 40